Moody Aldrich Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Moody Aldrich Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-224,831	Closed	-$3.33M	–	215
2024 Q1	$3.33M	Buy	+224,831	New	+$2.62M	0.57%	77
2021 Q1	–	Sell	-101,161	Closed	-$4.69M	–	192
2020 Q4	$4.69M	Buy	101,161 +35,454	+54%	+$1.41M	0.76%	65
2020 Q3	$2.16M	Buy	65,707 +952	+1%	+$29.2K	0.45%	87
2020 Q2	$1.78M	Sell	64,755 -20,030	-24%	-$658K	0.38%	87
2020 Q1	$2.54M	Sell	84,785 -89	-0.1%	-$2.36K	0.77%	57
2019 Q4	$2.35M	Buy	84,874 +1,311	+2%	+$29.8K	0.48%	82
2019 Q3	$1.52M	Sell	83,563 -842	-1%	-$18.6K	0.4%	83
2019 Q2	$2.07M	Buy	+84,405	New	+$1.27M	0.53%	71

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Moody Aldrich Partners's IOVA Position: Q2 2024 in Review

Moody Aldrich Partners sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 224,831 shares — an estimated $3.33M sold.

Moody Aldrich Partners first reported a position in IOVA in Q2 2019 and held it in 8 quarters. The position peaked at $4.69M in Q4 2020. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

Moody Aldrich Partners reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
Moody Aldrich Partners sold 224,831 Iovance Biotherapeutics shares in Q2 2024, an estimated $3.33M.
Moody Aldrich Partners first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 8 quarters.
Moody Aldrich Partners's Iovance Biotherapeutics position peaked at $4.69M in Q4 2020.
295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.